These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synthesis of MUC1 glycopeptide thioesters and ligation via direct aminolysis. Wilkinson BL; Chun CK; Payne RJ Biopolymers; 2011; 96(2):137-46. PubMed ID: 20564042 [TBL] [Abstract][Full Text] [Related]
5. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells. Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389 [TBL] [Abstract][Full Text] [Related]
6. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615 [TBL] [Abstract][Full Text] [Related]
7. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein. Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835 [TBL] [Abstract][Full Text] [Related]
9. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894 [TBL] [Abstract][Full Text] [Related]
10. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793 [TBL] [Abstract][Full Text] [Related]
11. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480 [TBL] [Abstract][Full Text] [Related]
12. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer. Glaffig M; Palitzsch B; Hartmann S; Schüll C; Nuhn L; Gerlitzki B; Schmitt E; Frey H; Kunz H Chemistry; 2014 Apr; 20(15):4232-6. PubMed ID: 24623572 [TBL] [Abstract][Full Text] [Related]
13. Synthetic glycopeptides for the development of cancer vaccines. Liakatos A; Kunz H Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400 [TBL] [Abstract][Full Text] [Related]
14. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes. Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates. Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901 [TBL] [Abstract][Full Text] [Related]
16. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures. Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769 [TBL] [Abstract][Full Text] [Related]
17. Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4. Dziadek S; Brocke C; Kunz H Chemistry; 2004 Sep; 10(17):4150-62. PubMed ID: 15352098 [TBL] [Abstract][Full Text] [Related]
18. Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response. Cai H; Huang ZH; Shi L; Sun ZY; Zhao YF; Kunz H; Li YM Angew Chem Int Ed Engl; 2012 Feb; 51(7):1719-23. PubMed ID: 22247051 [No Abstract] [Full Text] [Related]
19. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines. Xiao A; Zheng XJ; Song C; Gui Y; Huo CX; Ye XS Org Biomol Chem; 2016 Jul; 14(30):7226-37. PubMed ID: 27380866 [TBL] [Abstract][Full Text] [Related]
20. Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity. Westerlind U; Schröder H; Hobel A; Gaidzik N; Kaiser A; Niemeyer CM; Schmitt E; Waldmann H; Kunz H Angew Chem Int Ed Engl; 2009; 48(44):8263-7. PubMed ID: 19718733 [No Abstract] [Full Text] [Related] [Next] [New Search]